Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
Clinical trial NCT04340362 · COMPLETED
Trial details
- NCT number
- NCT04340362
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-08
- Primary completion
- 2021-11-11
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.